|
Market Closed -
London S.E.
01:35:13 02/10/26 am AEST
|
5-day change | 1st Jan Change | ||
| 1,795.00 GBX | -2.02% |
|
-4.37% | -1.62% |
| 09:52pm | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| 01/10 | European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading | MT |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 73,408 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 0.28% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 94,650 | 91,925 | 89,105 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 7.98% | -2.88% | -3.07% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.2x | 11.7x | 10.8x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | 4.51x | 4.53x | 3.99x | 3.53x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -1.64x | 0.5x | 1.32x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.16x | 2.07x | 2x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.79x | 2.59x | 2.43x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.25x | 7.49x | 7.01x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.18x | 8.32x | 7.73x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 16.9x | 16.1x | 13.4x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.91% | 6.23% | 7.49% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6958 | 0.7494 | 0.7843 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.8% | 4.09% | 4.28% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.289 | 1.566 | 1.694 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 54% | 47.9% | 46.3% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,920 | 35,498 | 36,615 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,473 | 12,275 | 12,711 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,310 | 11,046 | 11,531 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,191 | 6,209 | 6,755 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 21,242 | 18,517 | 15,696 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 18.32 | 18.32 | 18.32 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 9/2/22 | 1/2/23 | 31/1/24 | 5/2/25 | 4/2/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.22x | 2.79x | 8.25x | 3.8% | 97.46B | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 25.71x | 6.26x | 16.67x | 2.4% | 386.13B | |
| Weighted average by Cap. | 31.65x | 7.59x | 18.63x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
